SCHEMBL23950258

SCHEMBL23950258

COc1ccc2c(c1)c(CCNC(C)=O)cn2CCS(=O)(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 14/20 0.69
MTNR1B P49286 12/20 0.69
NQO2 P16083 4/20 0.69
HDAC3 O15379 3/20 0.68
HDAC6 Q9UBN7 3/20 0.68
HDAC4 P56524 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61
HDAC2 Q92769 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC9 Q9UKV0 1/20 0.61
AKR1C3 P42330 1/20 0.56
HTR2B P41595 2/20 0.54
HTR2C P28335 1/20 0.54
ROCK1 Q13464 1/20 0.53
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A1 P04798 1/20 0.50
MPO P05164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23950254 0.94 HDAC3 (0.71) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL23925220 0.93 HDAC3 (0.73) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL23950141 0.89 MTNR1A (0.69) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL16068348 0.85 HDAC3 (0.73) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL8717163 0.85 MTNR1A (0.74) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL23950140 0.83 MTNR1A (0.71) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL5144427 0.82 MTNR1A (1.00) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL16068372 0.82 HDAC3 (0.68) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL1067941 0.80 MTNR1A (0.78) MTNR1AMTNR1BNQO2HDAC3HDAC6
SCHEMBL30852855 0.80 MTNR1A (0.78) MTNR1AMTNR1BNQO2HDAC3HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323917-A1 MELATONIN DERIVATIVES, METHOD THEREOF, AND USE THEREOF XIAMEN NUOKANGDE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323917-A1 MELATONIN DERIVATIVES, METHOD THEREOF, AND USE THEREOF MTNR1A, MTNR1B, INMT MTNR1A 1/4885MTNR1B 2/4885NQO2 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.